Glaxo Group Limited

Caroline Jane Day

Naimisha Trivedi

Leanda Jane Kindon

David George Allen

Goran Kragol

Andrew Jonathan Whitehead

Darko Filic

Zorica Marusic-Istuk

Christopher David Edlin

Reshma Manesh Chudasama

Julien Bruno Douillet

Rodger Phillip Barnett

Thierry Boyer

Richard Anthony Henson

The compound 3'-N-demethyl-4&#x2033;-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I): or a salt thereof, compositions comprising the compound, its use in the treatment of neutrophil dominated inflammatory diseases, and methods for its preparation.

Anti-infammatory macrolide

The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl) (methyl)amino]octanoyl}amino)benzamide, whose formula is or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).

Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

A method of preparing a compound of formula (I), and pharmaceutically acceptable salts and solvates thereof. Polymorphs of this compound and their use as PPAR ligands are also disclosed 

Process for preparing a thiazole PPAR-ligand and polymorphs thereof

Growing community of inventors

Stevenage, United Kingdom

Caroline Jane Day